Latigo Biotherapeutics, Inc.

Moreover, the Company is subject to risks and uncertainties as a result of global business, political and macroeconomic events and conditions, including increasing financial market volatility and uncertainty, inflation, interest rate fluctuations, uncertainty with respect to the federal budget and debt ceiling and potential government shutdowns related thereto, potential instability in the global banking system, cybersecurity events, the impact of war or military conflict, including regional conflicts around the world, and public health pandemics.

SEC original ↗Latigo Biotherapeutics, Inc. — 10-Q Quarterly report10-QSep 3, 2026

The Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments if the Company s leases do not provide an implicit rate.

SEC original ↗Latigo Biotherapeutics, Inc. — 10-Q Quarterly report10-QSep 3, 2026

The Company determines its incremental borrowing rate based on the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment.

SEC original ↗Latigo Biotherapeutics, Inc. — 10-Q Quarterly report10-QSep 3, 2026

Change of Control Derivative Liability The Series 2026A unsecured convertible promissory notes (the Convertible Notes) contain a change of control repayment premium that is required to be bifurcated from the debt host and accounted for separately as a derivative liability under ASC 815, Derivatives and Hedging.

SEC original ↗Latigo Biotherapeutics, Inc. — 10-Q Quarterly report10-QSep 3, 2026

This feature is not clearly and closely related to the debt host because it provides for a repayment amount substantially in excess of par plus accrued interest and is contingently exercisable upon the occurrence of a corporate transaction event.

SEC original ↗Latigo Biotherapeutics, Inc. — 10-Q Quarterly report10-QSep 3, 2026

The derivative liability was initially recognized at fair value, with an offsetting debt discount recorded as a reduction of the carrying amount of the Convertible Notes.

SEC original ↗Latigo Biotherapeutics, Inc. — 10-Q Quarterly report10-QSep 3, 2026

“With a strong balance sheet, a highly experienced team, and a portfolio of differentiated programs, we are focused on executing our development plans, including the initiation of the Phase 3 program for onzotrigine and the advancement of onzotrigine and LTG-321 toward key future milestones.

SEC original ↗Latigo Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Sep 3, 2026

You can identify forward-looking statements because they contain words such as “expect,” “intend,” “may,” “plans,” or “will,” or similar expressions which concern our strategy, plans, projections, or intentions.

SEC original ↗Latigo Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Sep 3, 2026

All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding future events, our business strategy, and the plans and objectives of management for future operations, are forward-looking statements.

SEC original ↗Latigo Biotherapeutics, Inc. — 10-Q Quarterly report10-QSep 3, 2026

We may form or seek collaborations or strategic alliances, enter into licensing arrangements or other business transactions in the future, and we may not realize the benefits of such transactions.

SEC original ↗Latigo Biotherapeutics, Inc. — 10-Q Quarterly report10-QSep 3, 2026

GAAP, the Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value.

SEC original ↗Latigo Biotherapeutics, Inc. — 10-Q Quarterly report10-QSep 3, 2026

Any forward-looking statements in this press release are based on the Company’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.

SEC original ↗Latigo Biotherapeutics, Inc. — Earnings release (8-K exhibit)EX-99Sep 3, 2026

Legal Proceedings 39 Item 1A.

SEC original ↗Latigo Biotherapeutics, Inc. — 10-Q Quarterly report10-QSep 3, 2026

102 Signatures 103 i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this Quarterly Report) contains forward-looking statements about us and our industry that involve substantial risks and uncertainties.

SEC original ↗Latigo Biotherapeutics, Inc. — 10-Q Quarterly report10-QSep 3, 2026

These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

SEC original ↗Latigo Biotherapeutics, Inc. — 10-Q Quarterly report10-QSep 3, 2026

1 These forward-looking statements reflect our management s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Quarterly Report and are subject to risks and uncertainties.

SEC original ↗Latigo Biotherapeutics, Inc. — 10-Q Quarterly report10-QSep 3, 2026

Given these uncertainties, you should not place undue reliance on these forward-looking statements.

SEC original ↗Latigo Biotherapeutics, Inc. — 10-Q Quarterly report10-QSep 3, 2026